Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 30 vs ALEVE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain,Fever
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Naproxen is extensively metabolized in the liver primarily via CYP2C9 to 6-O-desmethyl naproxen, and less than 5% is excreted unchanged in urine.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
>99% bound to albumin; saturable at high concentrations.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
0.16 L/kg; indicates distribution primarily in extracellular fluid.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
Oral: ~95%; immediate-release formulation.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
GFR 30-59 m L/min: reduce dose and avoid long-term use; GFR <30 m L/min: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Child-Pugh class A: no adjustment; Child-Pugh class B or C: avoid use.
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
2-12 years: 2.5-5 mg/kg/dose orally every 8-12 hours; maximum 10 mg/kg/day. 12 years and older: same as adult.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
Initiate at lowest effective dose (220 mg every 12 hours); maximum 440 mg per day; monitor renal function and GI bleeding risk.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. Naproxen is contraindicated for treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease or GI bleeding are at greater risk.
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure and edema,Renal toxicity,Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic toxicity (inhibition of platelet aggregation),Exacerbation of asthma,Hepatic effects,Pregnancy: avoid during third trimester
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in the setting of CABG surgery,Advanced renal disease,History of gastrointestinal bleeding or perforation related to previous NSAID therapy,Active gastrointestinal bleed
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Avoid concurrent use of alcohol as it increases GI bleeding risk. No specific food restrictions; taking with food or milk may reduce dyspepsia. High potassium foods (e.g., bananas, spinach) may increase hyperkalemia risk in patients with renal impairment.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arteriosus premature closure risk begins. Third trimester: High risk of premature closure of ductus arteriosus, oligohydramnios, necrotizing enterocolitis, intracranial hemorrhage, and renal impairment; avoid after 30 weeks.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
Excreted in breast milk in low concentrations (M/P ratio ~0.12); relative infant dose <1% of maternal weight-adjusted dose. Compatible with breastfeeding; monitor infant for potential adverse effects (gastrointestinal upset, rash) at higher doses.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
No specific pharmacokinetic-based dose adjustments; however, use lowest effective dose for shortest duration, especially after 20 weeks. Avoid use after 30 weeks gestation due to fetal risks. Increased volume of distribution may reduce serum concentrations but no dose adjustment recommended.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
ALEVE (naproxen sodium) is a nonsteroidal anti-inflammatory drug (NSAID) with a longer half-life (12-17 hours) allowing twice-daily dosing. It carries a boxed warning for cardiovascular and gastrointestinal risk. Use lowest effective dose for shortest duration. Contraindicated in patients with aspirin allergy, perioperative pain in CABG surgery, and significant renal impairment. Monitor renal function in elderly, volume-depleted patients, and those on ACE inhibitors or diuretics.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
Take with food or milk to reduce GI upset.,Do not exceed 2 tablets (440 mg) in 24 hours unless directed by a doctor.,Avoid alcohol consumption to lower risk of GI bleeding.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not use with other NSAIDs (e.g., ibuprofen, aspirin) unless prescribed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 30 vs ALEVE, answered by our medical review team.
ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. ALEVE is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 30 and ALEVE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. The standard adult dose of ALEVE is: 220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 30 and ALEVE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. ALEVE is classified as Category C. First trimester: Risk of spontaneous abortion and cardiac defects (odds ratio 1.86 for NSAIDs). Second trimester: Possible fetal renal dysfunction and oligohydramnios; ductus arter. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.